Outcomes and Predictors of 30-Day Readmission in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization between 2016 and 2018

Outcomes and Predictors of 30-Day Readmission in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization between 2016 and 2018

Background: Hepatocellular carcinoma (HCC) is the third leading cause of cancer death worldwide. The 5-year survival rate for liver cancer in the US has improved from 3% four decades ago to 20% now. Transarterial chemoembolization (TACE) is the treatment of choice for stage B/intermediate-stage HCC....

Full description

Bibliographic Details
Main Authors: Ifrah Fatima, Mohamed Ahmed, Wael T. Mohamed, Vinay Jahagirdar, Kevin F. Kennedy, Alisa Likhitsup
Format: Article
Language:English
Published: MDPI AG 2024-01-01
Series:Gastroenterology Insights
Subjects:
transarterial chemoembolization
hepatocellular carcinoma
readmission
hepatic encephalopathy
weight loss
cirrhosis
Online Access:https://www.mdpi.com/2036-7422/15/1/6

Internet

https://www.mdpi.com/2036-7422/15/1/6

Similar Items